

Supplemental Table 1. Antihypertensive drugs according to medication strategies

	N, (%)
Monotherapy	653 (30.8)
Calcium channel blockers (CCB)	324 (49.6)
Renin-Angiotensin system (RAS) blockers	126 (19.3)
Diuretics	122 (18.7)
Beta-blockers (β blockers)	67 (10.3)
Centrally active drug	12 (1.8)
Vasodilator	2 (0.3)
Two-drug strategies	927 (43.6)
Diuretics + RAS blockers*	387 (41.7)
CCB + RAS blockers*	240 (25.9)
CCB + Diuretics *	140 (15.1)
CCB + β blockers*	61 (6.6)
β blockers + RAS blockers	38 (4.1)
Diuretic + β blockers *	37 (4.0)
Centrally active drug + Other drug class	20 (2.2)
Vasodilator + Other drug class	4 (0.4)
Three-drug strategies	425 (20.0)
CCB + Diuretics + RAS blockers*	230 (54.1)
Diuretics + β blockers + RAS blockers	84 (19.8)
CCB + β blockers + RAS blockers	45 (10.6)
CCB + Diuretics + β blockers *	26 (6.1)
Centrally active drug + Other drug class	23 (5.4)
Vasodilator + Other drug class	15 (3.5)
2 RAS blockers + Other drug class	2 (0.4)
Four-drug strategies	107 (5)
CCB + Diuretics + β blockers + RAS blockers	79 (73.8)
Centrally active drug + Other drug class	17 (15.9)
Vasodilator + Other drug class	6 (5.6)
2 RAS blockers + Other drug class	4 (3.7)
Five-drug strategies and more †	11 (0.4)
CCB + Diuretics + β blockers + RAS blockers + Centrally active drug	4 (40.0)
CCB + Diuretics + β blockers + RAS blockers + Vasodilator	4 (40.0)
CCB + Diuretics + RAS blockers + Centrally active drug + Vasodilator	1 (10.0)
Diuretics + β blockers + 2 RAS blockers + Centrally active drug	1 (10.0)

Legend: β blockers: Beta blockers, CCB: Calcium channel blockers, RAS blockers: Renin-Angiotensin System blockers

*Combination therapy recommended

† Patient with six-drug strategies were not presented

Supplemental Table 2: Treatments characteristics by country among treated patients

	Niger	Togo	Benin	Guinea	Mozambic	Dem. Rep of the Congo	Congo	Senegal	Côte d'Ivoire	Cameroon	Mauritania	Gabon
N, (%)	71(3.7)	104 (4.9)	246 (11.6)	170 (8.0)	148 (7.0)	255 (12.0)	177 (8.3)	142 (6.7)	292 (13.7)	354 (16.7)	84 (3.9)	80 (3.8)
Blood pressure control* (Uncontrolled vs controlled), N (%)	65 (84.4)	77 (72.6)	142 (57)	125 (73.5)	119 (80.4)	232 (89.2)	134 (75.3)	128 (80.5)	228 (77.8)	285 (76.6)	68 (81)	89 (100)
NA	3	0	1	2	0	1	0	1	2	3	0	0
Therapeutic Strategies, N (%)												
Monotherapy	10 (14.1)	14 (13.5)	72 (29.3)	76 (44.7)	66 (44.6)	123 (48.2)	24 (13.6)	40 (28.2)	74 (25.3)	101 (28.5)	23 (27.4)	30 (37.5)
Two-drug strategies	31 (43.7)	44 (42.3)	120 (48.9)	89 (52.4)	47 (31.8)	88 (34.5)	80 (45.2)	60 (42.3)	140 (47.9)	153 (43.0)	39 (46.4)	36 (45.0)
Three and more drugs strategies	30 (42.3)	46 (44.2)	54 (22.0)	5 (2.9)	35 (23.6)	44 (17.3)	73 (41.2)	42 (29.6)	78 (26.7)	100 (28.2)	22 (26.2)	14 (17.5)

* Uncontrolled hypertension was defined by a systolic BP (SBP) \geq 140 mm Hg and/or a diastolic BP (DBP) of \geq 90 mmHg on either of office BP measures in the clinic

Supplemental Table 3: Linear regression coefficient of sociodemographic and treatments factors for severity of hypertension in univariate analysis

	N	Linear regression coefficients	CI 95%	P value
Age	1017	-0.0021	-0.006 – 0.002	0.32
Sex (Male versus Female)	1023	0.087	-0.012 – 0.186	0.08
Patient Wealth index:	1004			0.10
Low versus high		0.15	0.0012 – 0.305	
Middle versus high		0.009	-0.101 – 0.12	
Location : urban versus rural	1001	-0.011	-0.136 – 0.112	0.86
Therapeutic strategy:	1023			<0.01
Monotherapy versus two-drugs		-0.106	-0.22 – 0.007	
Three-drugs and more versus two-drugs		0.155	0.037 – 0.273	
Antihypertensive drug class:				
Calcium channel blockers	1023	0.107	0.008 – 0.207	0.03
Diuretics	1023	0.136	0.039 – 0.233	<0.01
RAS blockers : ACEI	1023	0.043	-0.057 – 0.144	0.39
RAS blockers : ARB	1023	0.090	-0.05 – 0.231	0.21
Beta blockers	1023	-0.015	-0.131 – 0.099	0.797
Prescription of generic drug	731	0.025	-0.099 – 0.147	0.68
Use of traditional medicine	976	0.168	0.045 – 0.291	<0.01

Legend: Linear regression coefficients derived from separated linear regression with a random effect on country

to account for inter-country variability